Signaling Pathway and Molecular-Targeted Therapy for Hepatocellular Carcinoma (Q37914630)

25 August 2017

1 reference

title

Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma (English)

1 reference

25 August 2017

Signaling Pathway and Molecular-Targeted Therapy for Hepatocellular Carcinoma (English)

1 reference

9 December 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21829020

9 December 2024

targeted therapy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21829020

9 December 2024

Masatoshi Kudo

1

0 references

language of work or name

1 reference

9 August 2011

1 reference

full work available at URL

25 August 2017

https://www.karger.com/Article/Pdf/327562

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21829020

9 December 2024

1 reference

25 August 2017

volume

29

1 reference

25 August 2017

issue

3

1 reference

25 August 2017

page(s)

289-302

1 reference

Hepatocellular carcinoma pathogenesis: from genes to environment

25 August 2017

cites work

1 reference

Pathogenesis of hepatocellular carcinoma and molecular therapies.

21 January 2018

1 reference

Genomics and signaling pathways in hepatocellular carcinoma.

21 January 2018

1 reference

Genetics of hepatocellular tumors.

21 January 2018

1 reference

Molecular targeted therapies in hepatocellular carcinoma

21 January 2018

1 reference

Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer

21 January 2018

1 reference

Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma

21 January 2018

1 reference

Expressions of basic fibroblast growth factor and its receptors and their relationship to proliferation of human hepatocellular carcinoma cell lines

21 January 2018

1 reference

Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy

21 January 2018

1 reference

21 January 2018

The Hallmarks of Cancer

1 reference

Targeted therapy for hepatocellular carcinoma

21 January 2018

1 reference

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

21 January 2018

1 reference

Increased MAPK Expression and Activity in Primary Human Hepatocellular Carcinoma

21 January 2018

1 reference

Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis

21 January 2018

1 reference

Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.

21 January 2018

1 reference

Raf: a strategic target for therapeutic development against cancer

21 January 2018

1 reference

Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma

21 January 2018

1 reference

C-raf expression in early rat liver tumorigenesis after promotion with polychlorinated biphenyls or phenobarbital

21 January 2018

1 reference

Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma.

21 January 2018

1 reference

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

21 January 2018

1 reference

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

21 January 2018

1 reference

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

21 January 2018

1 reference

The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma

21 January 2018

1 reference

Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9.

21 January 2018

1 reference

Pivotal role of mTOR signaling in hepatocellular carcinoma

21 January 2018

1 reference

mTOR inhibitors for hepatocellular cancer: a forward-moving target

21 January 2018

1 reference

The biology of vascular endothelial growth factor

21 January 2018

1 reference

VEGF-A splicing: the key to anti-angiogenic therapeutics?

21 January 2018

1 reference

Angiogenesis in liver disease

21 January 2018

1 reference

Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis

21 January 2018

1 reference

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

21 January 2018

1 reference

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

21 January 2018

1 reference

Sunitinib and the benefits of a negative study.

21 January 2018

1 reference

EGFR antagonists in cancer treatment

21 January 2018

1 reference

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer

21 January 2018

1 reference

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

21 January 2018

1 reference

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

21 January 2018

1 reference

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

21 January 2018

1 reference

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

21 January 2018

1 reference

A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas

21 January 2018

1 reference

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

Drug development of MET inhibitors: targeting oncogene addiction and expedience

21 January 2018

1 reference

The role of the IGF axis in hepatocarcinogenesis

21 January 2018

1 reference

Differential roles of insulin-like growth factor receptor- and insulin receptor-mediated signaling in the phenotypes of hepatocellular carcinoma cells

21 January 2018

1 reference

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan

21 January 2018

1 reference

The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy

21 January 2018

1 reference

Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version

21 January 2018

1 reference

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

21 January 2018

1 reference

Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.

21 January 2018

1 reference

A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

21 January 2018

1 reference

Des-γ-Carboxyprothrombin May Be a Promising Biomarker to Determine the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000327562

1 reference

25 August 2017

1 reference